Background--Plasma adiponectin levels have previously been inversely associated with carotid intima-media thickness (IMT), a marker of subclinical atherosclerosis. In this study, we used a sex-stratified Mendelian randomization approach to investigate whether adiponectin has a causal protective influence on IMT.
A diponectin, a hormone with paracrine and endocrine effects, is secreted from adipose tissue and circulates in large amounts (3 to 30 mg/L) in plasma. In experimental studies, it enhanced insulin sensitivity and exerted atheroprotective effects. 1 Adiponectin effects are mediated by 3 receptors, adiponectin receptor 1, adiponectin receptor 2, and T-cadherin, of which the first 2 have intracellular domains 2, 3 and diverse abilities to regulate downstream inflammatory cytokine responses. 4 Low adiponectin levels are associated with obesity and related cardiovascular risk factors (type 2 diabetes mellitus [T2D], 1 endothelial dysfunction, 1 and dyslipidemia 5 ). Low adiponectin is also inconsistently [6] [7] [8] [9] associated with increased risk of myocardial infarction, whereas high adiponectin is associated with increased mortality in populations with high cardiovascular risk. [10] [11] [12] Moreover, adiponectin is inversely associated with carotid intima-media thickness (IMT), a marker of cardiovascular disease (CVD) risk, [13] [14] [15] [16] independent of established risk factors. Evidence suggests that IMT may be used as a surrogate marker for atherosclerotic processes 16, 17 and future cardiovascular events. [18] [19] [20] It has yet to be demonstrated whether adiponectin levels have a direct (rather than an indirect) effect on CVD. In addition, it is unclear whether the significantly higher adiponectin levels observed in women compared with men contribute to the striking sex difference in CVD risk. By combining extensive ultrasound measures of IMT with plasma adiponectin levels and adiponectin-associated genetic variants identified in a multiethnic genomewide meta-analysis (n=45 891), 21 we used a Mendelian randomization approach 22 to explore whether adiponectin has a causal influence on carotid IMT in men and women in a large (n=3430) European cohort with high CVD risk.
Materials and Methods
The IMPROVE Cohort IMPROVE has been described previously. 23 Briefly, persons with at least 3 classic CVD risk factors who were free of clinical CVD at enrollment were recruited. Blood samples were drawn at baseline and stored appropriately. A structured medical history was obtained, and standard clinical and biochemical phenotyping was carried out. Plasma adiponectin concentration was analyzed with a double-antibody radioimmunoassay (Millipore). The total coefficients of variation were 15.2% at low levels (2 to 4 lg/mL) and 8.8% at high levels (26 to 54 lg/mL). T2D was defined as a diagnosis of diabetes, antidiabetic therapy, or fasting glucose ≥7 mmol/L at the baseline examination. In addition, persons who started insulin treatment before the age of 50 years were excluded. The
Framingham risk score was calculated for all participants. 24 A total of 3711 participants were recruited from 7 centers in Finland, Sweden, the Netherlands, France, and Italy between 2002 and 2004.
Carotid Ultrasound Examination
The carotid ultrasound protocol and precision of the ultrasonographic measurements have been reported previously. 23 The far walls of the left and right common carotid artery (CC) and carotid bifurcation (Bif) were visualized in anterior, lateral, and posterior projections and recorded on VHS videotapes. IMT measurements were performed in a centralized laboratory (Department of Pharmacological Sciences, University of Milan, Italy). A dedicated software (M 0 Ath; Metris, SRL) that allowed semiautomatic edge of the echogenic lines of the intimamedia complex was used. The entire lengths of the far walls of the CCs and the Bifs were measured in at least 3 different frames. The mean IMT (IMT mean ) of each segment was calculated (based on 6 measurements for each segment), and the maximum IMT (IMT max ) for each segment was identified.
Measurements were taken at baseline and 30 months. Progression at 30 months, expressed in mm/year, was calculated by linear regression of IMT changes over time. All scans for each patient were assigned to a single reader after coding and were read blindly. As reported previously, 23 the intrasonographer intraclass correlation coefficents were 0.95 and 0.92 for CC-IMT mean and Bif-IMT mean , respectively. The intersonographer intraclass correlation coefficents for the same carotid segments were 0.89 and 0.95, respectively.
Cardiovascular Events and Follow-up
Occurrence of cardiovascular end points (myocardial infarction, angioplasty, diagnosis of angina pectoris, angioplasty, coronary artery bypass grafting and/or sudden cardiac death, ischemic stroke, transient ischemic attack, peripheral revascularization, and/or diagnosis of intermittent claudication) was monitored after 30 months. Diagnoses of incident angina pectoris, myocardial infarction, and ischemic stroke in the course of the study were based on European Society of Cardiology guidelines.
1,2 Surgery or endovascular procedures on the carotid arteries were not included as study end points because they might be related to the baseline ultrasound examination. All events were validated by local specialists using medical records and death certificates and were adjudicated subsequently by a designated specialist who was blinded to the clinical history and IMT data. Coronary events were defined as myocardial infarction, sudden cardiac death, angina pectoris, percutaneous coronary angioplasty, or coronary artery bypass grafting.
Ethics Committee Approval
All participants provided written informed consent. The study was approved by local ethics committees at the participating institutions.
Single-Nucleotide Polymorphism Selection and Genotyping
Adiponectin-associated single-nucleotide polymorphisms (SNPs) from a large recent report by Dastani et al 21 were considered for inclusion in an allelic score. SNPs and proxies used in the allelic score are presented in Table 1 . SNPs associated with T2D, diabetes-related traits, lipid traits, and SNPs in the IRS1 locus 25 were excluded to avoid analyzing pleiotropic effects, leaving rs2791553, rs3001032, rs925735, rs12051272, rs1597466, rs6810075, rs998584, and rs592423 to be included in the allelic score (SNPs marked with an asterisk in Table 1 ). DNA was available for all participants. High-throughput genotyping was performed using the Illumina 200K CardioMetabo chip (SNP Technology Platform, Uppsala University, Sweden), and standard quality control procedures were applied: SNPs were excluded for failing Hardy-Weinberg equilibrium (P<1910 À6 ) or call rate (95%) tests. Participants were excluded because of low call rate (<95%), ambiguous sex, cryptic relatedness, or non-European descent. Multidimensional scaling components were calculated using PLINK, 26 and components 1 to 3 were included as covariates in genetic analyses to control for population structure. SNPs not present on the CardioMetabo chip were genotyped using TaqMan SNP genotyping assays (Applied Biosystems), and consistent quality control parameters were applied. After quality control, 3430 subjects with genetic information, adiponectin levels, and IMT measures were included (women, n=1777; men, n=1653; age range 54 to 79 years). 27 Cohort characteristics are described in Table 2 .
Statistical Methods
Differences in plasma adiponectin across centers were analyzed by Kruskal-Wallis nonparametric 1-way analysis of variance, and the Jonckheere-Terpstra test for ordered alternatives was used to assess trends by latitude.
Associations among adiponectin levels, population structure (multidimensional scaling components [MDS] 1 to 3), and established CVD risk factors were investigated by calculation of Spearman rank correlation coefficients. Following this, skewed variables were natural log-transformed for normalization prior to further statistical analysis. Analysis of factors associated with plasma adiponectin was performed by multiple linear regression analysis (IBM SPSS Statistics 19.0). Linear regression analysis was conducted to assess associations between adiponectin levels and IMT variables. Analyses were stratified for sex because there were significant differences in adiponectin levels between men and women. Adjustments were made for age (basic model) or for age, body mass index, T2D, systolic blood pressure, current smoking, triglycerides, high-density lipoprotein cholesterol, and C-reactive protein (full model). Inclusion of waist-hip ratio in the full model instead of body mass index made little or no difference for the findings. Similarly, replacing current smoking with quintiles of pack-years had negligible effects on the results. Tests for sex-adiponectin interaction were performed for the entire cohort. Cox proportional hazards analysis adjusting for baseline characteristics in basic and full models, as specified, was used to determine association of plasma adiponectin with cardiovascular events and coronary events only. The proportionality assumption was tested with time-dependent variables.
For the Mendelian randomization, an unweighted allelic score was constructed by calculating the sum of alleles associated with increased plasma adiponectin divided by the maximum number of possible adiponectin-raising alleles. To account for possible population structure, MDS 1 to 3 were included as covariates in regression models. MDS (comparable with principal component analysis) was performed using largely uncorrelated CardioMetabochip SNPs obtained by applying a filter of pairwise correlations of r 2 <0.5 within a 50-SNP window that iteratively shifted 5 SNPs along the sequence. The first component corresponded well with the latitude of the recruitment center, whereas the second approximated longitude. Analysis of allelic score associations with IMT were performed with basic (adjusting for population structure and age) and full (adjusting for population structure, age, body mass index, systolic blood pressure, high-density lipoprotein cholesterol, triglycerides, C-reactive protein, current smoking, T2D) linear regression models. Tests of sex-allelic score interactions were performed for the entire cohort. Multiple testing correction was not applied to the analysis of IMT variables because the phenotypes are closely interrelated. 23 
Results
Baseline characteristics and ultrasonographic variables are presented in Table 2 . Men and women differed for most variables including adiponectin levels, which were higher in women (median 14.1 [interquartile range 8.7 to 22.0] versus 8.2 [interquartile range, 5.0 to 12.2] lg/mL). Adiponectin levels also differed across centers, with significantly lower adiponectin levels in the north observed in both men and women ( Figure 1 ). Of note, MDS component 1 (to a large degree reflecting south-to-north population structure) was associated with adiponectin and accounted for 16.5% and 8.0% of adiponectin variation in women and men, respectively (Table 3) . Sex-specific associations between adiponectin and established cardiovascular risk factors are shown in Table 4 . Adiponectin levels were inversely associated with blood pressure, body mass index, triglycerides, creatinine, C-reactive protein, and T2D and were positively associated with age and high-density lipoprotein cholesterol.
Adiponectin Levels and Baseline IMT
In men, adiponectin levels were inversely associated with CC-IMT mean and Bif-IMT mean and Bif-IMT max , but only the associations with Bif-IMT mean remained significant after adjustment for established CVD risk factors (Table 5 ). In women, adiponectin was inversely associated with the means of both CC-IMT and Bif-IMT in the basic model; however, further adjustment attenuated the association. Sex interacted with adiponectin to significantly influence Bif-IMT max in the fully adjusted model but not in the basic model (Table 5) .
Adiponectin Levels and Progression of IMT
In men, adiponectin levels were inversely associated with progression of CC-IMT mean and CC-IMT max , despite adjustment for established cardiovascular risk factors (Table 6) , whereas the association with Bif-IMT mean was lost when adjusting for the full model. In women, an inverse association with progression of Bif-IMT max was observed in the basic model only. Sex interacted significantly with adiponectin to influence progression of CC-IMT mean and CC-IMT max but not Bif-IMT mean or Bif-IMT max .
Adiponectin Levels and Cardiovascular Events
During follow-up, there were 74 and 117 cardiovascular events (45 and 75 coronary events) among women and men, respectively. In univariate analysis, age, body mass index, high-density lipoprotein cholesterol, triglycerides, creatinine, C-reactive protein, and T2D were associated with cardiovascular events in women, whereas age, systolic blood pressure, creatinine, and current smoking were associated with cardiovascular events in men (Table 7) . Adiponectin levels were associated with coronary events in women in the basic model (hazard ratio 
Mendelian Randomization Analysis
To assess causality (and avoid reverse causation), a Mendelian randomization approach 22 was used. If higher adiponectin levels have a direct causal role in reducing IMT measures, then genetic variants that increase adiponectin levels throughout life would be expected to demonstrate an association with lower IMT measures. Consequently, associations between an allelic score of adiponectin-increasing SNPs 21 and IMT measures were investigated.
The allelic score explained 1.7% and 1.2% of variation in baseline plasma adiponectin levels in men and women, respectively. The allelic score was inversely associated with systolic blood pressure (men and women) and glucose (women only) ( Table 8) . It is worth noting that women with the least adiponectin-increasing alleles had higher levels of adiponectin than the men with the highest allelic scores (Table 9) .
In men, the allelic score was inversely associated with baseline Bif-IMT mean and Bif-IMT max in the basic and full models (Table 10; Figure 2 ). In women, no associations with IMT were detected. There was a sex-allelic score interaction for Bif-IMT mean and Bif-IMT max (Table 10) . No allelic score associations were observed with IMT progression measures (data not shown).
Allelic Score and Incident CVD Events
The allelic score was inversely associated with coronary events in men (but not women) in the basic and full models (Table 11) . Men with the lowest allelic scores, 0 to 40, had more incident coronary events than men with higher allelic scores (Figure 3 ). Men, lg/mL 6.5 (3.9 to 11.0) 7.8 (4.8 to 11.9) 8.1 (4.9 to 12) 8.6 (5.7 to 12.8) 9.7 (5.9 to 14.5)
Values are median (interquartile range).
Discussion
This study is the first to address the issue of whether adiponectin has direct effects on CVD, using molecular genetics, plasma adiponectin measurements, and repeated carotid IMT imaging in the longitudinal IMPROVE study. 23 Furthermore, as this was the largest single study of adiponectin in relation to IMT to date, we were able to examine sex-specific effects of adiponectin on IMT in the CC and the Bif of the carotid artery. Whereas other studies have reported associations between adiponectin and IMT, [13] [14] [15] [16] this report highlighted differences in the effect of adiponectin along the carotid tree: Adiponectin levels were associated with the Bif-IMT at baseline and with progression of the CC. It should be noted that baseline associations reflect lifetime (≥60 years) exposure to plasma adiponectin levels and the allelic score, whereas progression of CC-IMT reflects 30 months of exposure. These findings may be relevant in light of differences between CC-IMT and Bif-IMT; in general, CC-IMT is not a measure of atherosclerosis but rather a thickening of the media in response to age and high shear stress and is associated with hypertension and prevalent stroke. 28, 29 Carotid atherosclerosis occurs predominantly in the Bif 19 in an area of low shear stress, and Bif-IMT is associated primarily with coronary heart disease risk factors and prevalent coronary heart disease. 19, 28 Of note, it is possible that our finding that levels of adiponectin showed a north-south trend (lower in the north), even after adjustment for established cardiovascular risk factors, might contribute to the previously demonstrated opposite north-south gradient in IMT (larger in the north) 23 ;
however, further work is required to confirm this finding.
To assess causality, we used Mendelian randomization to demonstrate causal effects of adiponectin on the carotid tree, using an allelic score of adiponectin-increasing SNPs determined in a large multiethnic analysis of 45 891 persons. 21 To minimize pleiotropic effects, SNPs significantly associated with T2D, diabetes-related traits, and lipid traits were excluded from the allelic score. Despite this, associations with systolic blood pressure (in women and to some extent in men) and fasting glucose (in women only) were observed. In men, we could show that the allelic score was associated with Bif-IMT and could provide support for a protective role of adiponectin in early atherosclerosis, as assessed by IMT; however, it should be noted that the effect of adiponectin (plasma levels and score) was modest and limited to the Bif and thus cannot be generalized to the rest of the carotid artery. It is worth noting that in this cohort with high CVD risk, the majority of participants were on lipid-lowering and/or antihypertensive medication. Analysis of untreated participants only is underpowered (n=372 men, n=368 women) but demonstrates effect sizes comparable to the whole cohort (data not shown). Similarly, stratification (rather than adjustment) for T2D status might be preferable but would severely limit power. Differences in effect of either adiponectin or allelic score on all studied phenotypes were minimal between the whole population and participants with or without T2D (data not shown).
The Framingham risk score 24 suggests that certain CVD risk factors are more important than others. Calculation of the Framingham risk score indicates that 1358 men and 632 women in this study were classified as being at high risk of CVD (Framingham risk score >0.20). Considering only this subset of the population, effect sizes were generally stronger than in the whole population, with the same phenotypes demonstrating significance for baseline IMT (but not progression) in analysis of either adiponectin (data not shown) or allelic score (Table 12) .
In addition, we demonstrated that there are sex-specific effects: Adiponectin levels and allelic scores were associated with IMT measures of the carotid Bif in men but not in women (even after adjustment for established cardiovascular risk factors), and adiponectin levels were associated with coronary events in women but not in men. That associations with IMT are not consistent with those for coronary events is not a surprise. As noted, baseline IMT measures of the carotid Bif can be considered a surrogate marker for the development of atherosclerosis from birth until enrollment in the study (over a time span of %65 years). In contrast, the cardiovascular events are acute incidents due to plaque rupture and atherosclerosis. Consequently, the 2 parameters studied reflect different components of CVD.
The sex-specific differences in effect of adiponectin on CVD may be due to the differences in levels of adiponectin between men and women. Because the effects of adiponectinraising alleles in women on IMT measures were negligible, it could be hypothesized that women with low adiponectin still have enough adiponectin to prevent or slow atherosclerosis development. In contrast, men with few adiponectin-raising alleles (allelic score 0 to 40) had very low adiponectin levels (6.5 lg/mL, interquartile range 3.9 to 11.0 lg/mL), which may be permissive of the atherosclerosis process compared with men with higher allelic scores (allelic score >70 to 100) and higher adiponectin levels (9.7 lg/mL, interquartile range 5.9 to 14.5 lg/mL).
Strengths and Limitations
A limitation of this study is the lack of information regarding hormone replacement therapy. Accordingly, complete assessment of the effect of female sex hormones on adiponectin is not possible. We cannot rule out that this might contribute to the sex differences reported. In addition, our results are primarily informative for participants with high cardiovascular risk and may not pertain to the general population. Furthermore, during the review process, a number of reports were published demonstrating associations between T2D-relevant traits and the loci that previously did not show evidence of pleiotropy, hence we cannot exclude pleiotropic effects of the allelic score. The lack of association between the plasma adiponectin and coronary events in men might be due to lack of statistical power. Despite these limitations, the IMPROVE study has comprehensive measurements of IMT at baseline and after 30 months in addition to adiponectin levels and dense genotyping. Furthermore, information on cardiovascular events is complete for 94.5% of participants over 3 years, limiting any follow-up bias. Although consistent, the effects of plasma adiponectin levels and allelic scores on Bif-IMT were much smaller than those provided by established CVD risk factors. In summary, this study fills a gap in the field and adds some support for a causal relationship between adiponectin and IMT.
Conclusions
This report provides some evidence of adiponectin protecting against atherosclerosis; however, this effect is limited to a specific part of the carotid artery (the Bif) and only to men, and the magnitude is modest. Mechanistic studies are warranted to clarify the exact nature of the effect. by the UK Medical Research Council (K013351), the Economic and Social Research Council and the Academy of Finland. The University College London Genetics Institute supported S.Sh. 
